|
"A comprehensive, collaborative elections resource."
|
As opioid deaths rise, pharma firm hikes price of antidote more than six-fold
|
Parent(s) |
Issue
|
Contributor | RP |
Last Edited | RP Feb 01, 2017 01:10pm |
Logged |
0
|
Category | General |
Author | Shefali Luthra |
Media | Newspaper - Philadelphia Inquirer |
News Date | Monday, January 30, 2017 03:35:00 PM UTC0:0 |
Description | First came Martin Shkreli, the brash young pharmaceutical entrepreneur who raised the price for an AIDS treatment by 5,000 percent. Then, Heather Bresch, the CEO of Mylan, who oversaw the price hike for its signature Epi-Pen to more than $600 for a twin-pack, though its active ingredient costs pennies by comparison.
Now a small Virginia company called Kaleo is joining their ranks. It makes an injector device that is suddenly in demand because of the nation’s epidemic use of opioids, a class of drugs that includes heavy painkillers and heroin.
And as demand for Kaleo’s product has grown, the privately held firm has raised its twin-pack price to $4,500, from $690 in 2014. |
Share |
|
2¢
|
|
Article | Read Full Article |
|
Date |
Category |
Headline |
Article |
Contributor |
|
|